# US 2022/0023385 A1 · Engineered fibroblast growth factor variants combined with engineered hepatocyte growth factor variants for treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0023385 A1
- Document ID: US20220023385A1
- Status: Published application
- Kind: A1
- Application number: 17/283,913
- Filed: 2019-10-09
- Published: 2022-01-27
- Earliest claimed: 2018-10-09
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Jennifer R. COCHRAN; David Myung
- Web page: https://patentgrep.com/patent/US20220023385A1

## CPC

- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61P 27/02: Ophthalmic agents
- C07K 14/50: Fibroblast growth factor [FGF]
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides polypeptide variants for use in treatment, in particular variants of fibroblast growth factor (FGF) and variants of hepatocyte growth factor (HGF) for use in combination to treat corneal epithelial defects (PCEDs) and/or corneal neovascularization.

## Claims

### Claim 1

A method of treating and/or preventing persistent corneal epithelial defects (PCEDs) in a subject in need thereof, the method comprising administering an human hepatocyte growth factor (hHGF) variant and an human fibroblast growth factor 1 (FGF1) variant to the subject, thereby treating and/or preventing said PCED.

### Claim 2

A method of treating, reducing, and/or preventing corneal neovascularization in a subject in need thereof, the method comprising administering an hHGF variant and an FGF variant to the subject, thereby treating, reducing, and/or preventing said corneal neovascularization.

### Claim 3 (depends on 1, 2)

The method according to claims 1 or 2, wherein said FGF1 variant comprises at least one member selected from the group consisting of an amino acid substitution, an amino acid deletion, an amino acid addition and combinations thereof, wherein the resulting FGF1 variant exhibits increased proteolytic stability as compared to wild-type FGF1 of SEQ ID NO:1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said FGF1 variant comprises an amino acid substitution, an amino acid deletion, an amino acid addition and combinations thereof in the β-loop or near the C-terminus.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to claims 1 to 4, wherein said FGF1 variant is a fibroblast growth factor receptor (FGFR) antagonist.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to claims 1 to 5, wherein said FGF1 variant comprises at least one amino acid substitution at position 28, 40, 47, 93 or 131.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprise at least one amino acid substitution selected from the group consisting of D28N, Q40P, S47I, H93G, L131R, and L131K.

### Claim 8 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprises amino acid substitution L131R.

### Claim 9 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprises amino acid substitution L131K.

### Claim 10 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprises amino acid substitutions D28N and L131R.

### Claim 11 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprises amino acid substitutions D28N and L131K.

### Claim 12 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprises amino acid substitutions Q40P, S47I, H93G and L131R.

### Claim 13 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprises amino acid substitutions Q40P, S47I, H93G and L131K.

### Claim 14 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprises amino acid substitutions D28N, Q40P, S47I, H93G and L131R.

### Claim 15 (depends on 6)

The method according to claim 6, wherein said FGF1 variant comprises amino acid substitutions D28N, Q40P, S47I, H93G and L131K.

### Claim 16 (depends on 6)

The method according to claim 6, wherein said FGF1 variant does not comprise the amino acid substitution L131A.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method according to claims 1 to 16, wherein said hHGF comprises at least one member selected from the group consisting of an amino acid substitution, an amino acid deletion, an amino acid addition and combinations thereof, as compared to wild-type hHGF of SEQ ID NO:8.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method according to claims 1 to 17, wherein said hHGF variant comprises at least one amino acid substitution at position 62, 127, 137, 170, or 193.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method according to claims 1 to 18, wherein said hHGF variant comprises at least one amino acid substitution selected from the group consisting of K62E, N127D/A/K/R, K137R, K170E, and N193D.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to claims 1 to 19, wherein said hHGF variant comprises amino acid substitutions K62E, N127D/A/K/R, K137R, K170E, and N193D.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method according to claims 1 to 20, wherein said hHGF variant is an antagonist of Met.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method according to claims 1 to 20, wherein said hHGF variant is an agonist of Met.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method according to claims 1 to 22, wherein said hHGF variant is conjugated to a member selected from the group consisting of a detectable moiety, a water-soluble polymer, a water-insoluble polymer, a therapeutic moiety, a targeting moiety, and a combination thereof.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method according to claims 1 to 22, wherein said hHGF variant further comprises amino acid substitutions at one or more of positions 64, 77, 95, 125, 130, 132, 142, 148, 154, and 173.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method according to claims 1 to 22, wherein said hHGF variant comprises a sequence selected from the group consisting of SEQ ID NOs: 2-22 from U.S. Pat. No. 9,556,248, provided in FIG. 41).

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method according to claims 1 to 22, wherein said hHGF variant comprises amino acid substitutions K62E, Q95R, I125T, N127D/A/K/R, I130V, K132N/R, K137R, K170E, Q173R, and N193D.

### Claim 27 (depends on 26)

The method according to claim 26, wherein said hHGF variant further comprises an amino acid substitution at one or more of positions 64, 77, 142, 148, and 154.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method according to claims 1 to 22, wherein said hHGF variant comprises amino acid substitutions K62E, Q95R, K132N, K137R, K170E, Q173R, and N193D.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said hHGF variant further comprises an amino acid substitution at one or more of positions 64, 77, 125, 127, 130, 142, 148, and 154.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method according to claims 1 to 22, wherein said hHGF variant comprises amino acid substitutions K62E, Q95R, N127D/A/K/R, K132N/R, K137R, K170E, Q173R, and N193D.

### Claim 31 (depends on 30)

The method according to claim 30, wherein said hHGF variant further comprises an amino acid substitution at one or more of positions 64, 77, 125, 130, 142, 148, and 154.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to claims 1 to 31, wherein said hHGF variant comprises a sequence selected from the group consisting of SEQ ID NOs: 2-22.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to claims 1 to 31, wherein said HGF variant is an agonist and said FGF1 variant is an antagonist.
